Rezultati - Carl Cook

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

    A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell... od Ezra E.W. Cohen, Kevin J. Harrington, David S. Hong, Ricard Mesı́a, Irene Braña, Pedro Pérez Segura, Trisha M. Wise‐Draper, Martin Scott, Patrick D. Mitchell, Ganesh Mugundu, Patricia McCoon, Carl Cook, Minal Mehta, Ulrich Keilholz

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial od Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul D. Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael A. Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: